![\"\"](\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2020\/07\/Screen-Shot-2020-07-20-at-7.33.58-AM-300x119.png\")
<\/a><\/p>\nCompany: Nurix Therapeutics, Inc.
\nSymbol: NRIX
\nDescription: They are a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders.
\nShares: 8.8 million
\nPrice Range: $16.00-$18.00
\nMarket Cap: $557m-$627
\nTrade Date: Friday, 7\/24
\nUnderwriter(s): JP Morgan, Piper Sandler, Stifel
\nCo-Manager: Needham
\nTerms Added: 7-20-20<\/p>\n
Company: Inozyme Pharma, Inc.
\nSymbol: INZY
\nDescription: They are a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton.
\nShares: 5 million
\nPrice Range: $14.00-$16.00
\nMarket Cap: $284m-$325m
\nTrade Date: TBD
\nUnderwriter(s): BofA Securities, Cowen, Piper Sandler
\nCo-Manager: Wedbush PacGrow
\nTerms Added: 7-20-20<\/p>\n
Company: Annexon, Inc.
\nSymbol: ANNX
\nDescription: They are a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye.
\nShares: 10 million
\nPrice Range: $14.00-$16.00
\nMarket Cap: $438m-$500m
\nTrade Date: Friday, 7\/24
\nUnderwriter(s): JP Morgan, BofA Securities, Cowen
\nTerms Added: 7-20-20<\/p>\n
Company: Vertex, Inc.
\nSymbol: VERX
\nDescription: Vertex delivers comprehensive tax solutions that enable global businesses to transact, comply and grow with confidence.
\nShares: 21.15 million
\nPrice Range: $14.00-$16.00
\nMarket Cap: $2.0bn-$2.3bn
\nTrade Date: Wednesday, 7\/29
\nUnderwriter(s): Goldman Sachs, Morgan Stanley, BofA Securities, Citigroup, Jefferies
\nCo-Manager: JMP Securities, Stifel, William Blair, CastleOak Securities, L.P.
\nTerms Added: 7-20-20<\/p>\n
Company: iTeos Therapeutics, Inc.
\nSymbol: ITOS
\nDescription: They are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients.
\nShares: 8.9 million
\nPrice Range: $16.00-$18.00
\nMarket Cap: $508m-$572m
\nTrade Date: Friday, 7\/24
\nUnderwriter(s): JP Morgan, SVB Leerink, Piper Sandler
\nCo-Manager: Wedbush PacGrow
\nTerms Added: 7-20-20<\/p>\n","protected":false},"excerpt":{"rendered":"
A total of five IPOs launched this morning (Monday, 7\/20). Four of the five are \u00a0to debut this week but will update the calendar when information becomes available. \u00a0This brings the total number of IPOs currently scheduled to debut this week up to six.<\/p>\n","protected":false},"author":4,"featured_media":13861,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24,2058,1536],"tags":[],"class_list":["post-13852","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ipo","category-spotlight","category-subscriber-content"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/13852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=13852"}],"version-history":[{"count":7,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/13852\/revisions"}],"predecessor-version":[{"id":13877,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/13852\/revisions\/13877"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media\/13861"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=13852"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=13852"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=13852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}